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Background: Diagnosis of encapsulating peritoneal sclerosis (EPS) is based on clinical 
symptoms, radiologic findings, and macroscopic or histological criteria. Two diagnostic scores 
for radiologic findings in computed tomography (CT) scans of patients with EPS have been 
established in the past (by Tarzi et al and Vlijm et al). The macroscopic appearance of EPS has 
previously been separated into three types. The use of CT scan as a tool to predict different 
macroscopic phenotypes, leading to specific surgical techniques and different medical treatment, 
has not yet been investigated.
Methods: We retrospectively analyzed 30 patients with late-stage EPS who underwent major 
surgery with peritonectomy and enterolysis. The preoperative CT scans were scored accord-
ing to the two aforementioned established diagnostic CT scores. The macroscopic phenotype, 
surgical procedure, and laboratory values at the time of surgery were evaluated. CT findings in 
the different macroscopic phenotypes were analyzed.
Results: All patients had highly predictive CT scores for EPS. The macroscopic Type III had 
significantly higher CT scores compared with the other macroscopic phenotypes. Patients with 
macroscopic Type I had significantly higher C-reactive protein values compared to EPS Type III. 
Operation time was significantly longer, and repeated surgery and intraoperative complications 
were more frequent in EPS Type I compared with EPS Type III (P,0.05). Using the CT score 
and CRP level, the sensitivities for prediction of EPS I and III were 78% and 87% with cor-
responding specificities of 67% and 93%.
Conclusion: Abdominal CT scans might help to identify patients with a higher risk of compli-
cations and provide important information for the surgical intervention prior to surgery.
Keywords: encapsulating peritoneal sclerosis, peritoneal dialysis, macroscopic phenotype, 
peritonectomy and enterolysis, PEEL, intraoperative findings, medical therapy in EPS
Introduction
Encapsulating peritoneal sclerosis (EPS) is a rare but severe complication of long-term 
peritoneal dialysis (PD). In the late stages of EPS, patients present mostly with signs 
of bowel obstruction, abdominal distension with abdominal pain, and weight loss. The 
incidence of EPS ranges between 0.3% and 8.1%.1–6 Although therapy has improved 
over the years, EPS-related morbidity and mortality are still high (mortality ranges 
from 19% to 55%),2–4,6–8 especially in the 1st year after diagnosis.
More than 10 years ago, the International Society of Peritoneal Dialysis defined 
the criteria for the diagnosis of EPS. Over the following years, several working groups 
refined these criteria and added further aspects; clinical signs and symptoms, and 
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CT scans using the two established CT scoring systems;28,29 
details of both scoring systems are tabulated in Tables 1 and 2. 
Using the CT scoring system of Tarzi et al28 (Table 1), two 
groups of patients were defined according the median CT 
scores of the study group: one group with CT scores of 10–22 
(high CT score) and one group with CT scores of 2.5–9 (low 
CT score). Owing to the dichotomous items used in the EPS 
scoring system of Vlijm et al29 (Table 2), no groups could be 
defined for further statistical analysis.
Macroscopic phenotypes of ePs
Three different macroscopic phenotypes of EPS have been 
characterized.18 Type I represents peritoneum with a sticky fibrin 
coating on top of the EPS membranes that contain the brown and 
thick peritoneum with rare interenteric sclerotic membranes. 
Table 1 cT scan scoring system by Tarzi et al
Peritoneal calcification Score
Not identified 0
localized area ,20% 1
.20% of peritoneum 2
.50% of peritoneum 3
extensive .80% 4
Bowel tethering
Not present 0
Mild tethering 1
Moderate tethering 2
Marked tethering 3
Peritoneal thickening
Not identified 0
localized area ,20% 1
.20% of peritoneum 2
.50% of peritoneum 3
extensive .80% 4
Loculation
Not present 0
,3 locules 1
3–6 locules 2
Multiloculated 3
Bowel wall thickening
Not identified 0
localized bowel 1
.20% of bowel 2
.50% of bowel 3
extensive .80% 4
Bowel dilatation
Not identified 0
localized bowel 1
.20% of bowel 2
.50% of bowel 3
extensive .80% 4
Notes: The maximum score is 22, and scores .2.5 are abnormal. cT scan scoring 
system by Tarzi et al.28
Abbreviation: cT, computed tomography.
radiological, macroscopic, and histological findings are the 
diagnostic pillars.9–14 Additionally, risk factors for the devel-
opment of EPS have been described: time on PD, younger 
age at start of PD, smoking, glucose exposure, and frequency 
and severity of peritonitis.2,3,6,9,15,16
The earlier stages of EPS are difficult to detect because 
clinical symptoms are lacking, and histological and radio-
logical findings are not specific. Changes in transporter 
status and ultrafiltration failure can be the first signs in the 
development of EPS.2 As previously reported, the time from 
the first onset of symptoms to the requirement for surgery is 
quite short.4,17,18 Evidence-based medical treatment options 
for patients with EPS are lacking, especially for those in the 
late stages of the disease.7,8,19  Corticosteroids are a widely 
discussed treatment option, particularly in patients with EPS 
with signs of systemic inflammation, associated with elevated 
C-reactive protein (CRP) values.13,19 A proportion of patients 
will develop clinical signs of bowel obstruction and require 
major surgery;20–26 outcome was improved by this treatment 
when carried out in experienced centers.20,22
We recently described different macroscopic  phenotypes 
of patients with EPS.18 Type I represents the inflamma-
tory type of the disease, whereas a resoluble, cobweb-like, 
interenteric sclerotic cover visible on top of the brown EPS 
membrane characterizes Type II. Type III is the classic type, 
with intestinal cocooning and a sclerotic capsular enclosing 
the whole intestine. Prior to surgery, computed tomography 
(CT) scans were routinely performed in all patients with 
EPS.27 Recently, Tarzi et al28 and Vlijm et al29 established 
two CT scoring systems for the diagnosis of EPS. To date, 
the use of CT scans as a tool to predict different macroscopic 
phenotypes, leading to specific surgical techniques and dif-
ferent medical treatment, has not yet been investigated.
Patients and methods
We included patients with EPS from our referral center that 
underwent peritonectomy and enterolysis (PEEL) between 
June 2005 and December 2013. All patients fulfilled all crite-
ria for the diagnosis of EPS,14,28–31 and were in the late stages 
of the disease with a requirement for major surgery.
The study protocol was approved by a local ethics com-
mittee in Germany (#322/2009BO1, Eberhard Karls Univer-
sity Tübingen, Germany). All patients gave written informed 
consent before participating in the study.
cT scans
All patients with EPS underwent CT scans of the abdomen and 
pelvis within a few days prior to surgery. Two experienced 
observers blinded to the intraoperative findings analyzed the 
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Type II is characterized by a fragile, cobweb-like interenteric 
sclerotic cover on top of the brown EPS membrane. Type III is 
the classic type with intestinal cocooning, and a sclerotic cap-
sule enclosing the whole intestine with a tendency to shrinkage, 
accompanied by interenteric sclerotic capsules.
surgical procedure
PEEL is a surgical procedure that goes beyond simple adhe-
siolysis and decortication of the EPS membranes. PEEL is 
regularly performed as total enterolysis with adhesiolysis of 
the encapsulated intestine. During this procedure, decortica-
tion of the sclerotic membranes is performed. PEEL results in 
restitution of the intestinal passage and prevention of recur-
rent disease by decortication and resection of the peritoneum 
(deserosation), or, if full peritonectomy is not possible, partial 
deserosation of the peritoneal membrane. The primary aim is 
to avoid intestinal perforation or injury to the serosa during 
serosal suturing or bowel resection.
statistical analysis
Continuous data are expressed as mean ± standard  deviation. 
All continuous variables were tested for normality using the 
Kolmogorov–Smirnov test. The median with an interquartile 
range was used where the distribution was not normal. 
Comparisons between different groups were performed 
with the Mann–Whitney U test or Fisher’s exact test, as 
appropriate. Analysis was performed using GraphPad Prism 
statistical software package (San Diego, CA, USA). P,0.05 
(two-tailed) was considered significant.
To predict EPS phenotypes based on the CT findings and 
the CRP value, a multiclass classification tree was constructed. 
To avoid an over-optimistic estimate of the misclassification 
rate, we judged its predictive ability by running a bootstrap 
method (R- package random Forest Survival, Regression and 
Classification). Similarly, the multiclass area under the curve 
(AUC) was estimated by cross-validation and with the help of 
the R-package receiver operating characteristic.
Results
clinical information of the study group
In total, 30 patients with late-stage EPS with a requirement 
for major surgery were included in the study. Clinical data 
from the study population are summarized in Table 3. Mean 
age at time of diagnosis was 52±11.8 years. There was a 
male predominance (24 men and six women). PD duration 
at time of surgery was 73 months (range, 57.8–106.5) and 
time between cessation of PD and surgery was 10 (2–23) 
months. Time from onset of symptoms associated with 
EPS to surgery was 4.5 months (range, 1.0–11.3). At the 
time of surgery, 20 patients had already been switched to 
hemodialysis, eight patients were switched to hemodialysis 
at the time of surgery, and two patients had a functioning 
transplant. CRP levels were elevated in 28 out of 30 patients, 
with median CRP levels of 2.6 mg/dL (range, 1.3–9.6; normal 
range, 0.1–0.5). The American Society of Anesthesiologists 
physical status32–34 was high in all patients (3±0.5), but no 
differences could be detected between the three different 
groups (P.0.05).
Regarding the surgical procedure, eleven patients required 
intestinal anastomosis due to bowel obstruction. Operation 
time was statistically significantly longer in EPS Type I than 
in EPS Type III (365±86.6 minutes vs 288±81.1 minutes) 
(P,0.05). The number of patients who needed reoperations 
(2±6 days after initial operation) was also higher in EPS 
Type I than in EPS Type III (P,0.05). Serosal defects with 
requirement for sutures or intestinal anastomosis (one patient) 
due to bowel injury (by the surgeon) was more frequently 
observed in patients with EPS Type I than in patients with 
EPS Types II and III (P,0.001).
Prior to surgery, six of 30 patients were treated with 
steroids, and only a small proportion of patients (two of 
30 patients) received tamoxifen. One patient received immu-
nosuppressive therapy after kidney transplantation. One 
patient was taking mycophenolate mofetil for treatment of 
systemic lupus erythematosus.
Radiological evaluation
CT scans prior to surgery were available for all 30 patients; 
21 scans were performed at our hospital, while the remain-
ing nine were performed by the referring physicians or in 
the transferring hospital. Twenty CT scans (67%) were 
performed using intravenous contrast medium (CM). 
The analysis of the two scoring systems is described in 
Tables 1 and 2. For the diagnosis of EPS, all patients had 
to have positive CT scores (with or without CM), using 
both of the established scoring systems.28,29 The details of 
the CT findings of our study population are summarized 
Table 2 cut-off values for a positive cT scan, using the cT scan 
scoring parameters of Vlijm et al
Item Positive/negative
Peritoneal thickening
Peritoneal calcification
Peritoneal enhancement
adhesions of bowel loops
signs of bowel obstruction
Fluid loculation/septation
Notes: every item is scored as positive or negative. Three of six items are required 
for a contrast-enhanced CT scan, and two of five items when no contrast enhancement 
is used. cut-off values for a positive cT scan, using the cT scan scoring parameters 
of Vlijm et al.29
Abbreviation: cT, computed tomography.
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in Tables 4 and 5 and Figure 1. The median score was four 
(range, 3–5) on the Vlijm et al system,29 and eleven (range, 
8–12) on the Tarzi et al system.28 In EPS Type I, only mild 
peritoneal calcification with extensive loculated ascites and 
adhesions of bowel loops was observed. CM enhancement 
of the peritoneum was a common finding in CM-enhanced 
CT scans in patients with Type III (Figure 1). Bowel wall 
thickening, dilatation, and tethering of the bowel, particu-
larly in the pelvis minor, were present in all three groups of 
patients (Figure 1). Extensive calcification of the peritoneal 
membrane with extensive peritoneal thickening was a com-
mon finding in EPS Type III (Figure 1).
Comparison of CT findings between  
the different macroscopic phenotypes
We compared the CT findings of the 30 patients with the 
intraoperative macroscopic phenotypes (Table 5). In all 
patients, bowel wall thickening, tethering of the bowel 
Table 4 Results of the cT scoring system in our study population 
using both established cT scoring systems
Variable Patients with EPS 
(n=30)
cT scoring system by Tarzi et al28 (IQR) 11 (8–12)
cT scoring system by Tarzi et al28 .2.5 30/30
cT scoring system by Vlijm et al29
 cM-enhanced cT scan 4±1
 Native cT scan 4±1
cT scoring system by Vlijm et al29
 cM-enhanced cT $3/6 22/22
 Native cT scan $2/5 8/8
Abbreviations: cT, computed tomography; IQR, interquartile range; cM, contrast 
medium; ePs, encapsulating peritoneal sclerosis.
Table 3 clinical data of study population
Variable Patients with 
late-stage EPS
Total number of patients 30
age (years ± sD) 52.3±11.8
Female/male 6/24
clinical criteria (Nakamoto14) fulfilled 30/30
PD duration at time of surgery (months) (IQR) 73 (57.8–106.5)
PeT at diagnosis of ePs
 low/low average 6/30
 high average/high 24/30
Daily urine output (ml) (IQR) 0.0 (0.0–495.0)
Peritonitis 59 in 2,573 
months; 1:44
Icodextrin 25/30
Diabetes 7/30
smoking 9/30
hypertension 27/30
hemoglobin (g/dl ± sD) (range; normal 13–18) 11.1±2.1
hematocrit ± sD 0.3±0.1
leukocytes (×109/l ± sD) (range; normal 4.0–11.3) 8.6±5.2
cRP (mg/dl, 0.1–0.5) (IQR) 2.6 (1.3–9.6)
Phosphate (mmol/l) (range; normal 0.68–1.68) 1.3±0.9
calcium (mmol/l ± sD) (range; normal 1.90–2.70) 2.2±0.3
PTh (pmol/l) (range; normal 1.1–7.3) 20.5 (5.1–40.1)
Urea-N (mg/dl ± sD) (range; normal 10–25) 81.3±35.3
creatinine (mg/dl ± sD) (range; normal 0.5–1.4) 6.7±2.5
IcU stay (days) ± sD 9.6±7.0
hospitalization (days) ± sD 36.8±24.3
cePs 23/30
PT-ePs 7/30
Body mass index at time of surgery ± sD 20.7±2.8
Time between cessation of PD and surgery (months), 
median (IQR)
10 (2–23)
Time from onset of symptoms to surgery (months), 
median (IQR)
4.5 (1.0–11.3)
Operation time (minutes) ± sD
 Type Ia 365±86.6.3
 Type II 346±117.82
 Type IIIa 288±81.1
Intestinal anastomosis during surgery due abdominal mass
 Type I 1/9*
 Type II 3/6*
 Type III 5/15*
suturing of serosa defects or anastomosis due to bowel injury
 Type Ib 7/9*
 Type II 0/6*
 Type III 0/15*
Reoperation after Peel
 Type Ia 4/9*
 Type II 0/6*
 Type III 1/15*
alive/dead at the time of follow-up  
(median 28.5 months; range, 3.8–62.5)
21/9
Death after surgery (during hospital stay)
 all patients 3/30
 Type I 2/9*
 Type II 1/6*
 Type III 0/15*
(Continued)
Table 3 (Continued)
Variable Patients with 
late-stage EPS
Reoperation because of recurrent ePs 3/30
alive/dead at the time of follow-up  
(median 28.5 months; range, 3.8–62.5)
21/9
Death after surgery 3/30
Death from ePs (total) 1
Death from other causes (total) 5
corticosteroid therapy prior to surgery 6/30
Tamoxifen therapy prior to surgery 2/30
asa class ± sD 3±0.5
Notes: *The first number (shown before “/”) indicates the number of patients with 
the noted variable, the second number (shown after “/”) indicates the number of 
patients with ePs Type I, Type II, or Type III, respectively. aP,0.05, bP,0.001. ePs 
commonly presents after peritoneal dialysis has been stopped, either PT-ePs or 
after switching to hemodialysis (cePs).
Abbreviations: sD, standard deviation; PD, peritoneal dialysis; IQR, interquartile 
range; PeT, peritoneal equilibrium test; cRP, c-reactive protein; PTh, parathyroid 
hormone; IcU, intensive care unit; Peel, peritonectomy and enterolysis; asa, 
american society of anesthesiologists; ePs, encapsulating peritoneal sclerosis; 
PT-ePs, post-transplantation ePs; cePs, classical ePs.
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(especially in the pelvis), dilatation of bowel loops, and 
peritoneal thickening could be detected. In EPS Types I and 
II, loculated ascites was significantly more common than 
in EPS Type III using the Vlijm et al29 score (P,0.01 and 
P,0.05). Furthermore, pronounced areas of calcifications of 
the peritoneal membrane were more common in EPS Type 
III than in Types II and I (P,0.01 and P,0.05, respectively) 
(Figure 1 and Table 5).
Using the CT score established by Tarzi et al,28 patients 
with macroscopic Type I showed a median CT score of 
eight (range, 8–11), whereas patients with EPS Type II 
had a median score of six (range, 5–7) (P,0.05). Median 
CT scores of 12 could be detected in patients with EPS 
Type III (range, 11–15). Patients with EPS Type III had 
significantly higher CT scores than patients with EPS Types I 
and II (P,0.01 and P,0.001) (Figure 2). Additionally, all 
patients with EPS Type III had CT scores .10 using the 
scoring system of Tarzi et al,28 whereas none of the patients 
with Type II had CT scores .9. In EPS Type I, 40% of the 
patients were in the high CT score group. CRP levels were 
statistically significantly higher in these patients compared 
to Type III (P,0.01).
There were no significant differences in CRP levels 
between Types I and II or between Types II and III (P=0.9 
and P=0.09).
Prediction of the macroscopic  
phenotype prior to surgery
Using the score from Vlijm et al,29 there was an overall error 
rate of 50% (multiclass AUC =0.62) in the prediction of the 
macroscopic phenotype. After the addition of CRP levels to 
the radiological findings, the overall error rate decreased to 
43% (multiclass AUC =0.70).
Taking into account the Tarzi et al28 score, the overall error 
rate in the prediction of the macroscopic phenotype was 33% 
(multiclass AUC =0.66). Using radiological findings used in 
Tarzi et al28 score in combination with CRP values resulted in 
an overall error rate of 23% (multiclass AUC =0.81).
Therefore, the Tarzi et al28 score in combination with CRP 
levels was used for further analyses. The sensitivity of the 
Table 5 CT findings in different macroscopic phenotypes of EPS 
(n=30)
Findings Type I 
(n=9)
Type II 
(n=6)
Type III 
(n=15)
Peritoneal thickening 9 5 15
Peritoneal calcification 2c,h 0d,i 11
Peritoneal cM enhancementb 4 2 3
Fluid loculation/septation 9e,i 6f,h 10
adhesions of bowel loopsb 5g,h 3 14
Bowel wall thickeninga 5 6 15
Bowel dilatationa 6 5 14
Bowel tetheringa 9 5 15
signs of bowel obstructionb 6 5 14
Notes: aItem used only in the scoring system by Tarzi et al;28 bitem is used only in 
the scoring system by Vlijm et al;29 cType I vs Type III; dType II vs Type III; eType I vs 
Type III; f Type II vs Type III; g Type I vs Type III; hP,0.05; iP,0.01.
Abbreviations: cT, computed tomography; ePs, encapsulating peritoneal sclerosis; 
cM, contrast medium.
Figure 1 cross-sectional abdominal cT images of ePs Type I–III patients.
Notes: In ePs Type I (A–D), only mild peritoneal calcification (thin arrows in B), 
extensive loculated ascites (thick arrows in A–D), air entrapment in ascites (thick 
arrow in D, no intestinal perforation was detected during Peel surgery), and 
adhesions of bowel loops with bowel wall thickening and dilatation are observed 
(A). cM enhancement of the peritoneum (thin arrows in C). ePs Type II (E–F) is 
showing adhesions of bowel loops with bowel wall thickening and dilatation (thick 
arrow in E) and loculated ascites (thin arrows in E), bowel tethering (thick arrow in 
F) and bowel dilatation (thin arrow in F). In ePs Type III (G–I), extensive calcification 
of the peritoneal membrane (G and H), including free-flowing ascites (thick arrows 
in G and H), and extensive peritoneal thickening (thin arrows in I) exist.
Abbreviations: cT, computed tomography; ePs, encapsulating peritoneal sclerosis; 
Peel, peritonectomy and enterolysis; cM, contrast medium.
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prediction of EPS Type I was 0.78 (95% confidence interval 
[CI] =[0.4 0.97]) with a specificity 0.76 (95% CI =[0.53 0.92]). 
The positive predictive value was 0.58 (95% CI =[0.28 0.85]) and 
the negative predictive value was 0.89 (95% CI =[0.65 0.99]), 
with a misclassification rate of 0.23 (95% CI =[0.1 0.42]). The 
sensitivity of the prediction of EPS Type II was 0.5 (95% CI 
=[0.12 0.88]) and the specificity was 0.96 (95% CI =[0.79 1]). 
The positive predictive value was 0.75 (95% CI =[0.19 0.99]) 
and negative predictive value was 0.88 (95% CI =[0.7 0.98]), 
with a misclassification rate of 0.13 (95% CI =[0.04 0.31]).
The prediction of EPS Type III had a sensitivity of 
0.87 (95% CI =[0.6 0.98]) and a specif icity of 0.93 
(95% CI =[0.68 1]). The positive predictive value was 0.93 
(95% CI =[0.66 1]), and the negative predictive value was 
0.88 (95% CI =[0.62 0.98]), with a misclassification rate of 
0.1 (95% CI =[0.02 0.27]) (Figures 2 and 3).
Discussion
In this retrospective single-center study, we used CT param-
eters from two established CT scores to investigate the 
differences between CT findings prior to surgery and the 
macroscopic phenotype in a large cohort of well-defined 
patients with EPS.28,29,35 In patients with late-stage EPS with 
symptoms of bowel obstruction, major surgery using PEEL or 
using decortication and enterolysis of the peritoneum seems 
to be the only established treatment option.4,19
In the current study, statistically significant differences in 
the CT scores were found for the macroscopic phenotypes. 
In all patients with EPS, bowel wall thickening, tethering of 
the bowel (especially in the small pelvis of EPS patients), 
dilatation of bowel loops, and peritoneal thickening occur. 
Patients with the typical cocooning and sparse exudations of 
the sclerotic capsule (Type III EPS) had higher CT scores than 
patients with the inflammatory Type I (sticky fibrin coating on 
top of the peritoneum). Nearly half (40%) of patients in the 
Type I group had CT scores .9; in these patients, CRP levels 
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Notes: Using the cT scoring system by Tarzi et al28 (A); and the cT scoring system 
by Vlijm et al29 (B).
Abbreviations: cT, computed tomography; sD, standard deviation; cRP, c-reactive 
protein; IQR, interquartile range; ePs, encapsulating peritoneal sclerosis.
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were significantly higher than that in patients in the Type III 
group. Additionally, the areas of calcifications were almost 
exclusively detected in patients with EPS Type III. In Type I 
EPS, pronounced loculated ascites dominated. Therefore, the 
combination of CT score, CRP levels, and the presence of 
calcification might be a useful tool to differentiate between 
Types I and III EPS with a sensitivity between 78% and 87% 
and a specificity of 67% and 93%. Especially, the differentia-
tion between EPS Type I and EPS Type III using simple tools 
(CT findings and CRP levels) has consequences in everyday 
clinical practice (eg, organization of the operation room plan 
due to different operation times depending on the macroscopic 
phenotype and selection of the surgeon).
In cases of requirement for major surgery, there were 
clear differences in the surgical techniques used for the 
inflammatory phenotype (Type I) and the classic phenotype 
(Type III), as shown by a shorter operation time for EPS Type 
III compared to EPS Type I.
In patients with EPS Type I, the surgical technique used 
is much more sophisticated because there is no separable 
sclerotic membrane covering the intestine, but rather a dif-
fuse, thin, and fragile fibrin membrane, and this is reflected 
in the higher numbers of patients requiring suturing of 
serosal defects or anastomosis during surgery or reoperation 
in EPS Type I compared with EPS Type III. Therefore, CT 
scans prior to surgery should be integrated into the surgi-
cal planning process to distinguish between the different 
macroscopic phenotypes of EPS in order to optimize the 
surgical procedure.
The study has several limitations, mostly due to its ret-
rospective character. No statistically significant differences 
could be detected between the groups of patients with high 
and low scores regarding outcome, but it should be noted that 
the study was not powered to find such a difference. Another 
limitation is the abundance of patients on hemodialysis in 
our cohort, and the fact that only seven patients had received 
a kidney transplant in the past (post-transplantation EPS). 
Therefore, there might be differences regarding the prediction 
of the macroscopic phenotype using the CT score in patients 
with post-transplantation EPS. As previously discussed 
regarding the CT score, the assessment of fluid loculation 
in patients still on PD or shortly after stopping PD might be 
challenging.
Different surgical procedures in late-stage patients with 
EPS have been described elsewhere.22,23,26,36 In our patient 
cohort, the operations were done by a single surgeon and were 
performed as previously described.22 Therefore, differences in 
operation time, intraoperative complications, and the number 
of particular features (eg, intestinal anastomosis) might be 
apparent using other surgical approaches.36,37 Furthermore, 
due to the retrospective study design, we could not definitively 
prove that using the CT score would have changed the surgical 
approach. A prospective study needs to address the clinical 
impact of the scoring system prior to surgery. To date, the 
different macroscopic phenotypes of EPS have been described 
only in 24 patients from our referral center. There is still discus-
sion whether these macroscopic phenotypes might represent 
different stages of the disease.38 Nevertheless, regardless of 
whether the different phenotypes might represent different 
stages of the disease, there is growing evidence that patients 
should be treated individually, based on the different changes in 
the peritoneal membrane.19 It is noteworthy that the numbers of 
patients included in this study are low and conclusions should 
therefore be treated with some caution.
In conclusion, surgical treatment of the inflammatory 
EPS Type I was associated with more intraoperative compli-
cations and a longer operation time with different surgical 
techniques. The combination of CT score, CRP levels, the 
presence of calcification, and the absence of fluid locations 
might be a useful tool to differentiate Type I from Type III 
prior to surgery.
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